Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-01
2008-07-01
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07393827
ABSTRACT:
Pharmaceutical compositions and methods for using are provided for restoring β-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a β-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.
REFERENCES:
patent: 5288721 (1994-02-01), Klein et al.
patent: 5340813 (1994-08-01), Klein et al.
patent: 5424286 (1995-06-01), Eng
patent: 5473070 (1995-12-01), Underiner et al.
patent: 5567704 (1996-10-01), Bianco et al.
patent: 5580873 (1996-12-01), Bianco et al.
patent: 5580874 (1996-12-01), Bianco et al.
patent: 5585380 (1996-12-01), Bianco et al.
patent: 5612349 (1997-03-01), Bianco et al.
patent: 5620984 (1997-04-01), Bianco et al.
patent: 5621102 (1997-04-01), Bianco et al.
patent: 5629315 (1997-05-01), Bianco et al.
patent: 5629423 (1997-05-01), Klein et al.
patent: 5648357 (1997-07-01), Bianco et al.
patent: 5652243 (1997-07-01), Bianco et al.
patent: 5670506 (1997-09-01), Leigh et al.
patent: 5739138 (1998-04-01), Bianco et al.
patent: 5770595 (1998-06-01), Klein et al.
patent: 5780476 (1998-07-01), Underiner et al.
patent: 5792772 (1998-08-01), Bianco et al.
patent: 5795897 (1998-08-01), Underiner
patent: 5795898 (1998-08-01), Brown et al.
patent: 5801182 (1998-09-01), Klein et al.
patent: 5804584 (1998-09-01), Underiner et al.
patent: 5807861 (1998-09-01), Klein et al.
patent: 5807862 (1998-09-01), Klein et al.
patent: 5817662 (1998-10-01), Klein et al.
patent: 5859018 (1999-01-01), Brown et al.
patent: 5866576 (1999-02-01), Underiner et al.
patent: 5889011 (1999-03-01), Klein et al.
patent: 5929081 (1999-07-01), Brown et al.
patent: 5965564 (1999-10-01), Bianco et al.
patent: 6020337 (2000-02-01), Leigh et al.
patent: 6043250 (2000-03-01), Klein et al.
patent: 6057328 (2000-05-01), Singer et al.
patent: 6075029 (2000-06-01), Klein et al.
patent: 6100271 (2000-08-01), Klein et al.
patent: 6103730 (2000-08-01), Klein et al.
patent: 6121270 (2000-09-01), Underiner et al.
patent: 6133274 (2000-10-01), Underiner et al.
patent: 6469017 (2002-10-01), Klaus et al.
patent: 6586429 (2003-07-01), Gong et al.
patent: 6693105 (2004-02-01), Underiner et al.
patent: 6774130 (2004-08-01), Klein et al.
patent: 6780865 (2004-08-01), Porubek et al.
patent: 6858576 (2005-02-01), Young et al.
patent: 6872700 (2005-03-01), Young et al.
patent: 6878715 (2005-04-01), Klein et al.
patent: 6902744 (2005-06-01), Kolterman et al.
patent: 6956026 (2005-10-01), Beeley et al.
patent: 2005/0233969 (2005-10-01), Dong
patent: 1 557 165 (2005-07-01), None
patent: WO 00/66128 (2000-04-01), None
patent: WO 00/61583 (2000-10-01), None
patent: WO 00/66128 (2000-11-01), None
patent: WO 2004/028524 (2004-04-01), None
Yang et al. “The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice,” Diabetologia, 2002, 45, 1307-14.
Eckhoff et al. “Suppression of the c-Jun N-terminal kinase pathway by 17b-estradiol can preserve human islet functional mass from proinflammatory cytokine-induced destruction,” Surgery, 2003, 134, 169-79.
Chen et al. “Lisofylline, a Novel Antiinflamatory Agent, Protects Pancreatic b-Cells from Proinflammatory Cytokine Damage by Promoting Mitochondrial Metabolism,” Endocrinology, 2002, 143, 2341-2348.
Xu et al. “Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats,” Diabetes, 1999, 48, 2270-6.
Augustyns et al. “Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes,” Exp. Opin. Ther. Patents, 2003, 13, 499-510.
von Herrath et al. “Progress in the Development of Immune-Based Therapies for Type 1 Diabetes Mellitus,” Biodrugs, 2006, 20, 341-50.
Abraham, E.J., et al., “Insulinotrophic Hormone Glucagon-Like Peptide-1 Differentiation of Human Pancreatic Islet-Derived Progenitor Cells into Insulin-Producing Cells,”Endocrinology,143(8):3152-3161 (2002).
Aliberti, J., et al., “Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity,”Nature Immunology,3(1):76-82 (2002).
Aziz, A., et al., “Exendin-4, a GLP-1 Receptor Agonist, Modulates the Effect of Macronutrients on Food Intake by Rats,”Nutritional Neurosciences,American Society for Nutritional Sciences, (Manuscript) pp. 990-995 (2002).
Bleich, D., et al., “Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-1 beta-induced dysfunction in cultured rat islets,”Endocrinology,137:4871-4877 (1996).
Bright, J.J., et al., “Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline,”Journal of Immunology,161:7015-7022 (1998).
Bulotta, A., et al., “Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1,”Journal of Molecular Endocrinology,29:347-360 (2002).
Bursten, S.L., et al., “Lisofylline causes rapid and prolonged suppression of serum levels of free fatty acids”Journal of Pharmacology&Experimental Therapeutics,284:337-345 (1998).
Buteau, J., et al., “Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation,”Diabetes,50:2237-2243 (2001).
Chakrabarti, S. K., et al., “Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1,”The Journal of Biological Chemistry,277(15):13286-13293 (2002).
Chakrabarti, S. K., et al., “Transcription factors direct the development and function of pancreatic beta cells,”Trends Endocrinol. Metab.,14:78-84 (2003).
Chen, M., et al., “Lisofylline, a Novel Antiinflammatory Agent, Protects Pancreatic β-Cells from Proinflammatory Cytokine Damage by Promoting Mitochondrial Metabolism,”Endocrinology,143(6):2341-2348 (2002).
Chen, Y.E., et al, “Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard,”The Journal of Biological Chemistry,272:4108-4115 (1997).
Coon, M. E., et al., “Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling,”Journal of Immunology,163:6567-6574 (1999).
Cottet, S., et al., “cFLIP protein prevents tumor necrosis factor-alpha-mediated induction of caspase-8-dependent apoptosis in insulin-secreting betaTc-Tet cells,”Diabetes,51:1805-1814 (2002).
Deleon, D. D., et al., “Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy,”Diabetes,52:365-371 (2003).
Delaporte, Q., et al., “Comparison between the growth pattern of cell cultures from normal and Duchenne dystrophy muscle,”Journal of Neurological Sciences,64:149-160 (1984).
Drucker, D., “Minireview: The Glucagon-Like Peptides,”Endocrinology,142(2):521-527 (2001).
Egan, J. M., et al., “Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes,”American Journal of Physiology Endocrinology&Metabolism,284(6):E1072-E1079 (2003).
Egan, J. M., et al., “GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells,”Diabetes/Metabolism Research Reviews,19:115-123 (2003).
Eng, J., et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas,”The Journal of Biological Chemistry,267(11):7402-7405 (1992).
Farilla, L., et al., “Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats,”Endocrinology,143(11):4397-4408 (2002).
Fine
Bradley Christina Marchetti
Diakine Therapeutics, Inc.
Nixon & Venderhye P.C.
Tsang Cecilia
LandOfFree
Pharmaceutical compositions and methods for restoring... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions and methods for restoring..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and methods for restoring... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2771391